News

Stay informed about the latest developments and industry news of Suzhou Fangzhou Biotechnology.

Company News

The 2018 doctoral thesis defense meeting of the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College was held.
2018
The 2017 doctoral thesis defense meeting of the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College was held.
2017
The American Association of Blood Banks (AABB) invited Dr. Guan Xin and others from our unit to give a special report at the 15th International Cord Blood Conference held in San Diego, USA in June 2017.
June 2017
Three of our latest research results were presented at the 58th Annual Meeting of the American Society of Hematology held in San Diego, California, USA, and won the annual meeting abstract achievement award at the same time.
2016
Three of our latest research results were presented at the 57th Annual Meeting of the American Society of Hematology held in Orlando, Florida, and won the annual meeting abstract achievement award at the same time.
2015
The research result abstract of our classmate Zhang Yu was accepted by the 77th Annual Meeting of the Japanese Society of Hematology held in Kanazawa, Japan. This research result will be presented as a poster at the conference.
2015
The fifth graduate thesis defense meeting of the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College was held.
June 25, 2015
The abstracts of three of our latest research results were accepted by the 2015 Experimental Biology Annual Meeting held in Boston. These research results will be presented as posters or academic reports at the conference.
2015
Four of our latest research results were accepted by the 56th Annual Meeting of the American Society of Hematology held in San Francisco. These research results will be presented as posters or academic reports at the conference.
2014
A seminar on the construction project of the Suzhou Fangzhou Pharmaceutical Innovation Drug Incubation Base was held in Kunming.
September 20, 2014
The fourth graduate thesis defense meeting of the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College was held.
May 25, 2014
A seminar on the iPS and stem cell project of the Suzhou Union Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College and the Tianjin Institute of Hematology of the Chinese Academy of Medical Sciences was held.
January 2014
A post - project self - inspection and experiment discussion meeting on the project "Establishment of Induced Pluripotent Stem Cell Bank and Its Application in Hematological Disease Treatment" was jointly held with the Tianjin Institute of Hematology.
2013
The 2013 annual academic report meeting of the Suzhou Union Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences was held.
2013
The Ministry of Human Resources and Social Security of the People's Republic of China approved the establishment of a national post - doctoral research workstation in our company.
March 31, 2012
The 2012 annual academic report meeting of the Suzhou Union Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences was held.
2012
The third graduate thesis defense meeting of the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College was held.
2012
In April 2012, the recombinant gene protein reagents and monoclonal antibody reagents developed by the Suzhou Fangzhou Biomedical R & D Center were launched on the market.
April 2012
The first graduate thesis defense of the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College was held.
May 8, 2010
Li Liming, the secretary of the Party Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College, inspected and investigated the Suzhou Fangzhou Biomedical R & D Center.
February 6, 2010
Notice on recruiting recommended postgraduate students by the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College.
August 20, 2009
Recruitment notice for post - doctors at the Suzhou Fangzhou Gene Pharmaceutical Co., Ltd. Sub - station of the Suzhou Industrial Park Post - doctoral Research Workstation and the Suzhou Fangzhou Biomedical R & D Center of the Chinese Academy of Medical Sciences and Peking Union Medical College.
March 20, 2009
In September 2005, the founder of the company won the "Outstanding Entrepreneurship Award" among the top 100 overseas Chinese professionals in the world.
September 2005
Our company was rated as one of the top 50 foreign - invested enterprises in Guangxi in 2001 by the Guangxi Association of Foreign - Invested Enterprises.
2001
Our company was rated as an honest taxpayer by the Guangxi Zhuang Autonomous Region State Taxation Bureau.
2000
Our company was recognized as a high - tech enterprise by the Ministry of Science and Technology of the People's Republic of China and the Guangxi Science and Technology Department respectively.
September 2000
The second - generation Fangzhou Yongdi (a Class I new drug) was recognized as the preferred project for the industrialization of the achievements of the National 863 Program by the Ministry of Science and Technology.
2000
Fangzhou Yongdi was recognized as a high - tech product by the Guangxi Science and Technology Department.
January 2000
The Ministry of Personnel of the People's Republic of China approved the establishment of a post - doctoral research workstation in our company.
December 2000
Fangzhou Yongdi was included in the National Torch Program.
1999
Our company's G - CSF production line passed the GMP certification.
December 1999
Fangzhou Yongdi was featured in a special program on the CCTV "Science and Technology Expo": "Fangzhou Yongdi, a representative of genetic engineering drugs, is an outstanding representative among cancer treatment adjuvant drugs."
November 1999
Fangzhou Yongdi (recombinant human granulocyte colony - stimulating factor, English name: rhG - CSF, formerly known as: Cutilin) was the first product independently developed by our company. In 1997, it was rated as a national new product by the Ministry of Foreign Trade and Economic Cooperation.
1997
Our company was rated as an advanced foreign - invested technology enterprise.
November 1997